These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 9410314)
21. Long-term results of neoadjuvant hormonal therapy prior to radical prostatectomy in patients with clinically localized prostate cancer: biochemical and pathological effects. Hara I; Miyake H; Hara S; Gotoh A; Eto H; Arakawa S; Kamidono S Hinyokika Kiyo; 2001 Jul; 47(7):453-8. PubMed ID: 11523127 [TBL] [Abstract][Full Text] [Related]
22. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. Gleave ME; Goldenberg SL; Chin JL; Warner J; Saad F; Klotz LH; Jewett M; Kassabian V; Chetner M; Dupont C; Van Rensselaer S; J Urol; 2001 Aug; 166(2):500-6; discussion 506-7. PubMed ID: 11458055 [TBL] [Abstract][Full Text] [Related]
23. Effect of neoadjuvant epirubicin and total androgen blockade on complete pathological response in patients with clinical stage T3/T4 prostate cancer. Francini G; Paolelli L; Francini E; Pascucci A; Manganelli A; Salvestrini F; Petrioli R Eur J Surg Oncol; 2008 Feb; 34(2):216-21. PubMed ID: 17502132 [TBL] [Abstract][Full Text] [Related]
24. [Hormone therapy of locally advanced and metastatic prostate carcinoma]. Rübben H Praxis (Bern 1994); 2001 Sep; 90(38):1641-4. PubMed ID: 11675917 [TBL] [Abstract][Full Text] [Related]
25. Re: Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? Messing EM J Urol; 2003 Nov; 170(5):1955; author reply 1955-6. PubMed ID: 14532828 [No Abstract] [Full Text] [Related]
26. [Is maximal androgenic blockade necessary in the treatment of prostatic cancer?]. Matveev BP; Bukharkin BV Urologiia; 2003; (6):6-10. PubMed ID: 14708235 [TBL] [Abstract][Full Text] [Related]
27. Endocrine therapy for prostate cancer. Damber JE Acta Oncol; 2005; 44(6):605-9. PubMed ID: 16165920 [TBL] [Abstract][Full Text] [Related]
29. [LHRH analogues for the treatment of prostate cancer: an evidence level-based analysis]. Pfitzenmaier J; Altwein JE Aktuelle Urol; 2009 Mar; 40(2):100-8. PubMed ID: 19253209 [TBL] [Abstract][Full Text] [Related]
30. [Future prospects for primary hormone therapy in localized and locally advanced prostate cancer]. Akaza H; Hirao Y; Labrie F; Soloway MS Hinyokika Kiyo; 2003 Dec; 49(12):771-7. PubMed ID: 14978964 [TBL] [Abstract][Full Text] [Related]
31. Long-term results of adjuvant hormonal therapy plus radiotherapy following radical prostatectomy for patients with pT3N0 or pT3N1 prostate cancer. Miyake H; Sakai I; Harada K; Hara I; Eto H Int J Urol; 2004 Jun; 11(6):397-401. PubMed ID: 15157209 [TBL] [Abstract][Full Text] [Related]
32. Significance of micrometastases in pelvic lymph nodes detected by real-time reverse transcriptase polymerase chain reaction in patients with clinically localized prostate cancer undergoing radical prostatectomy after neoadjuvant hormonal therapy. Miyake H; Kurahashi T; Hara I; Takenaka A; Fujisawa M BJU Int; 2007 Feb; 99(2):315-20. PubMed ID: 17155986 [TBL] [Abstract][Full Text] [Related]
33. Surgical pathology examination of radical prostatectomy specimens. Updated protocol based on the Italian TAP study. Mazzucchelli R; Montironi R; Prezioso D; Bono AV; Ferrari P; Manganelli A; Morelli P; De Vito ML; Santinelli A; Diamanti L; Lotti T; Polito M; Anticancer Res; 2001; 21(5):3599-607. PubMed ID: 11848530 [TBL] [Abstract][Full Text] [Related]
34. Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year followup. Garzotto M; Wajsman Z J Urol; 1998 Mar; 159(3):950-4; discussion 954-5. PubMed ID: 9474190 [TBL] [Abstract][Full Text] [Related]
35. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy. Kroepfl D; Loewen H; Roggenbuck U; Musch M; Klevecka V BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480 [TBL] [Abstract][Full Text] [Related]
36. Expression of insulin-like growth factor binding protein-3 before and after neoadjuvant hormonal therapy in human prostate cancer tissues: correlation with histopathologic effects and biochemical recurrence. Miyata Y; Sakai H; Kanda S; Igawa T; Hayashi T; Kanetake H Urology; 2004 Jun; 63(6):1184-90. PubMed ID: 15183987 [TBL] [Abstract][Full Text] [Related]
37. [Study of intermittent endocrine therapy in patients presenting with biologic recurrence after radical prostatectomy or radiotherapy]. de la Taille A; Zerbib M; Conquy S; Amsellem-Ouazana D; Saighi D; Debré B Prog Urol; 2002 Apr; 12(2):240-7. PubMed ID: 12108338 [TBL] [Abstract][Full Text] [Related]
38. [Adjuvant medical treatment or radiotherapy following radical prostatectomy or curative radiotherapy]. Guy L Bull Cancer; 2007 Jul; 94(7 Suppl):F15-20. PubMed ID: 17845989 [TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant hormone therapy: the Canadian trials. Klotz L; Gleave M; Goldenberg SL Mol Urol; 2000; 4(3):233-7;discussion 239. PubMed ID: 11062379 [TBL] [Abstract][Full Text] [Related]
40. Surgical and biologic outcomes after neoadjuvant bicalutamide treatment in prostate cancer. Gravina GL; Festuccia C; Galatioto GP; Muzi P; Angelucci A; Ronchi P; Costa AM; Bologna M; Vicentini C Urology; 2007 Oct; 70(4):728-33. PubMed ID: 17991545 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]